ArticleCell reports. Medicine2023
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Article
- Overcoming immunotherapy resistance in breast cancer: a novel strategy by targeting the integrated stress response.Frontiers in cell and developmental biology · 2026Review
- Computational decoding of cell-cycle phase effects on cancer hallmarks across breast cancer subtypes.Breast cancer research : BCR · 2025Article
- The interplay between driver mutation and oxidative stress in colorectal cancer: from pathogenesis to therapeutics.Journal of translational medicine · 2025Review
- Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.Journal for immunotherapy of cancer · 2025Article
- Harnessing Antioxidants in Cancer Therapy: Opportunities, Challenges, and Future Directions.Antioxidants (Basel, Switzerland) · 2025Review
- Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.NPJ breast cancer · 2025Article
- Organoids in breast cancer translational research: intersection of technologies.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.Journal of molecular neuroscience : MN · 2024Article
- A disulfiram derivative against lung cancer via the Notch signaling pathway without neurotoxicity and hepatotoxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Exploiting metabolic vulnerabilities in breast cancers with NF1 loss.Cell reports. Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Priska Auf der MaurTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: priska.aufdermaur@unibas.ch.
Marcel P TrefnyCancer Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Zora BaumannTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Milica VulinTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Ana Luisa CorreiaTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Maren DiepenbruckTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Nicolas KramerTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Katrin VolkmannTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Bogdan-Tiberius PrecaTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Pedro RamosOncology Research, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Cedric LeroyOncology Research, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Tobias EichlisbergerFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Katarzyna BuczakProteomics Core Facility, Biozentrum, University of Basel, Basel, Switzerland.
Federica ZilliTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Ryoko OkamotoTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Roland RadInstitute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München, München, Germany; Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technische Universität München, München, Germany; Department of Medicine II, Klinikum rechts der Isar, Technische Universität München, München, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael Rugaard JensenOncology Research, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Christine FritschOncology Research, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Alfred ZippeliusCancer Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael B StadlerFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland; Swiss Institute of Bioinformatics, Basel, Switzerland; Faculty of Science, University of Basel, Basel, Switzerland.
Mohamed Bentires-AljTumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. Electronic address: m.bentires-alj@unibas.ch.
University of Basel · CHNovartis (Switzerland) · CHFriedrich Miescher Institute · CHGerman Cancer Research Center · DESIB Swiss Institute of Bioinformatics · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
A genome-wide PiggyBac transposon-mediated screen and a resistance screen in a PIK3CA
Indexed as
Breast NeoplasmsAcetylcysteineAnimalsClass I Phosphatidylinositol 3-KinasesFemaleHumansMicePhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesThiazolesAcetylcysteineAlpelisibClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesThiazolesbreast cancercombination therapyPI3K alpha inhibitionresistancetransposon screen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.